Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2003
08/21/2003US20030157628 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157627 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157626 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157624 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157623 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157622 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157621 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157620 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157619 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157618 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157617 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157616 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157614 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157613 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157612 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157611 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157610 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157609 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157608 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157607 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157606 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157605 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157604 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157603 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157602 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/21/2003US20030157601 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes/adipocytes/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis
08/21/2003US20030157599 Comprises nucleotide sequence coding prostaglandin E receptor (EP3) for diagnosis and treatment of atherosclerotic diseases; restriction fragment length polymorphisms
08/21/2003US20030157577 Using myeloid cells which are expressing IAP (Integrin Associated Protein) and screening the substances (antibodies) having property of causing apoptosis
08/21/2003US20030157576 Epithelial cell growth inhibitors
08/21/2003US20030157569 Novel genes associated with the maintenance of differentiation of smooth muscle cells
08/21/2003US20030157567 In a polypeptide containing 11 amino acids and lysine 5 being conjugated with malonaldehyde (MDA), inhibits uptake by the high affinity low density lipoprotein (LDL) receptor of LDL or a partially modified form
08/21/2003US20030157562 Protein is characterized in that it elicits an immunological response from a mammal; has been prepared by expression in a bacterium other than Borrelia burgdorferi; free of other Borrelia proteins and has specific amino acid sequence
08/21/2003US20030157539 IRAK-M is a negative regulator of toll-like receptor signaling
08/21/2003US20030157530 cDNA for human methylenetetrahydrofolate reductase
08/21/2003US20030157525 Novel human G-protein coupled receptor, HGPRBMY31, and variants and methods of use thereof
08/21/2003US20030157522 Modulate apoptosis; autoimmune diseases, anticancer agents
08/21/2003US20030157521 Binding to monoclonal or polyclonal antibodies; anticancer, antitumor agents
08/21/2003US20030157516 Medical diagnosis; binding with adenine
08/21/2003US20030157512 Transmembrane protein; diagnosis of central nervous system disorders
08/21/2003US20030157485 Forensic analysis; chromosome marking
08/21/2003US20030157479 Antigen arrays for treatment of allergic eosinophilic diseases
08/21/2003US20030157191 Administering to a subject undergoing chemotherapy an amount of a chemoprotectant
08/21/2003US20030157183 Method for encapsulating fine solid particles in the form of microcapsules
08/21/2003US20030157178 Injectable depot composition
08/21/2003US20030157167 Oxymorphone controlled release formulations
08/21/2003US20030157163 Semipermeable walled container housing capsule comprising progestin and estrogen for sustained-release via osmotic pressure changes within
08/21/2003US20030157140 Parenteral preparation having structure of basement polymer layer, carrying layer containing objective substances selected from drugs, aroma chemicals, antigens; carrying layer sandwiched between basement and surface layers
08/21/2003US20030157134 Method for treating a non-rhinorrhea cholinergic influenced secretion
08/21/2003US20030157128 Comprises exogenous nucleotide sequences which encode exogenous amino acid sequences; infection of host cell with recombinant Yellow Fever Virus provides for expression of exogenous nucleic acid and production of antigen
08/21/2003US20030157127 Nutritious supplemental composition for suppression against onset of large intestinal cancer and manufacturing method thereof
08/21/2003US20030157124 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157121 Virulence genes, proteins, and their use
08/21/2003US20030157119 Methods for diagnosis and therapy of hematological and virus-associated malignancies
08/21/2003US20030157118 Tumour-specific animal proteins
08/21/2003US20030157116 Tlp peptides and dna sequences coding the same
08/21/2003US20030157115 Carrier with a dendrimeric poly-Lysine enabling multiple epitopes to be covalently attached thereto, a peptide with t epitope(s) and a carbohydrate with a b epitope that is not a sialoside; immunotherapy
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157106 Antibody which immunologically reacts with an interleukin 22 protein
08/21/2003US20030157103 Human amine transporter antibodies
08/21/2003US20030157102 Administering a ligand having a population of activated t cells and binding specificity for the extracellular domain of CD28 to enhance t cell proliferation and increase overall lymphokine levels
08/21/2003US20030157099 Human trk receptors and neurotrophic factor inhibitors
08/21/2003US20030157098 Methods for inhibiting brain tumor growth
08/21/2003US20030157096 Used to antagonize the effects of T-cell inducible factor in certain diseases
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157089 Polypeptides; inducting immunology response
08/21/2003US20030157088 Mixture of enzyme and enzyme inhibitors
08/21/2003US20030157087 Gastrointestinal disorders
08/21/2003US20030157085 Antitumor agents
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003US20030157081 Using chaperone protein; adjust gene expression
08/21/2003US20030157071 Hormone replacement therapy; transduction bone marrow cells; cell differentiation
08/21/2003US20030157069 Administering polypeptide; them radiation and drug therapy
08/21/2003US20030157064 Actin gene promoter; genetic engineered polypeptide; cardiovascular disorders
08/21/2003US20030157059 Vaccine; infection therapy
08/21/2003US20030157058 Troponin anti-metastatic therapeutic and method of use
08/21/2003US20030157056 Modified cytokines for use in cancer therapy
08/21/2003US20030157055 Modified cytokines for use in cancer therapy
08/21/2003US20030157054 Recombinant tumor specific antibody and use thereof
08/21/2003US20030157053 Administering mixture of apotosis agent and neutralizer thereof
08/21/2003US20030157029 Methods of administering and enhancing absorption of pharmaceutical agents
08/21/2003US20030155434 Spray nozzle apparatus and method of use
08/21/2003DE19937304C2 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists for the control of menopausal hot flushes
08/21/2003CA2516331A1 Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
08/21/2003CA2491547A1 Methods and composition for modulating type i muscle formation using pgc-1.alpha.-
08/21/2003CA2482633A1 Oligomeric molecules and uses thereof
08/21/2003CA2476556A1 Modulation of immune response by non-peptide binding stress response polypeptides
08/21/2003CA2476454A1 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003CA2476446A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003CA2476424A1 Means and methods for altering the motility of the gastrointestinal tract
08/21/2003CA2476292A1 Helical peptidomimetics
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476120A1 Methods and compositions for the treatment of eye diseases
08/21/2003CA2475972A1 Enzyme treatment of foodstuffs for celiac sprue
08/21/2003CA2475928A1 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475522A1 Method of radio-labelling biomolecules
08/21/2003CA2475388A1 Chimeric molecules for cleavage in a treated host
08/21/2003CA2475177A1 Materials and methods for preparing dimeric growth factors
08/21/2003CA2474885A1 Mutated gene coding for a lat protein and the biological applications thereof
08/21/2003CA2474844A1 Cks1 inhibitors
1 ... 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 ... 3163